Cargando…

A Rapid Immunization Strategy with a Live-Attenuated Tetravalent Dengue Vaccine Elicits Protective Neutralizing Antibody Responses in Non-Human Primates

Dengue viruses (DENVs) cause approximately 390 million cases of DENV infections annually and over 3 billion people worldwide are at risk of infection. No dengue vaccine is currently available nor is there an antiviral therapy for DENV infections. We have developed a tetravalent live-attenuated DENV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ambuel, Yuping, Young, Ginger, Brewoo, Joseph N., Paykel, Joanna, Weisgrau, Kim L., Rakasz, Eva G., Haller, Aurelia A., Royals, Michael, Huang, Claire Y.-H., Capuano, Saverio, Stinchcomb, Dan T., Partidos, Charalambos D., Osorio, Jorge E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046319/ https://www.ncbi.nlm.nih.gov/pubmed/24926294 http://dx.doi.org/10.3389/fimmu.2014.00263

Ejemplares similares

Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates
por: Strouts, Fiona R., et al.
Publicado: (2016)

Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax)
por: Huang, Claire Y.-H., et al.
Publicado: (2013)

Erratum: A Rapid Immunization Strategy with a Live-Attenuated Tetravalent Dengue Vaccine Elicits Protective Neutralizing Antibody Responses in Non-Human Primates
Publicado: (2014)

Preclinical Evaluation of the Immunogenicity and Safety of an Inactivated Enterovirus 71 Candidate Vaccine
por: Hwa, Shi-Hsia, et al.
Publicado: (2013)

A Novel MVA Vectored Chikungunya Virus Vaccine Elicits Protective Immunity in Mice
por: Weger-Lucarelli, James, et al.
Publicado: (2014)

Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine
por: Tsuji, Isamu, et al.
Publicado: (2021)

Influence of FcγRIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue Vaccine
por: Byers, Anthony M., et al.
Publicado: (2015)

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

A tetravalent dengue nanoparticle stimulates antibody production in mice
por: Silva, Elisângela F, et al.
Publicado: (2012)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
por: Hou, Jue, et al.
Publicado: (2022)

Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue Vaccine
por: DeMaso, Christina R, et al.
Publicado: (2022)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

The Immunodominance Change and Protection of CD4(+) T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice
por: Chen, Hsin-Wei, et al.
Publicado: (2015)

Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine
por: Zhao, Hui, et al.
Publicado: (2014)

Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control
por: THAVARA, U., et al.
Publicado: (2014)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines
por: Russell, Philip K., et al.
Publicado: (2016)

Design of Monovalent and Chimeric Tetravalent Dengue Vaccine Using an Immunoinformatics Approach
por: Dixit, Neeraj Kumar
Publicado: (2021)

Efficacy of Tetravalent Dengue Vaccine: A Systematic Review and Meta-Analysis
por: Khobragade, Ashish Wasudeo, et al.
Publicado: (2021)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

A tetravalent nanoparticle vaccine elicits a balanced and potent immune response against dengue viruses without inducing antibody-dependent enhancement
por: Chen, Qier, et al.
Publicado: (2023)

A Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human Primates
por: Swaminathan, Gokul, et al.
Publicado: (2016)

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy
por: Rabaa, Maia A, et al.
Publicado: (2017)

CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals
por: DiazGranados, Carlos A, et al.
Publicado: (2020)

A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates
por: Kwilas, Steve, et al.
Publicado: (2014)

In silico prediction of monovalent and chimeric tetravalent vaccines for prevention and treatment of dengue fever
por: Subramaniyan, Vijayakumar, et al.
Publicado: (2018)

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico
por: Dayan, Gustavo H, et al.
Publicado: (2014)

1051. Characterization of Immune Responses to a Live-Attenuated Tetravalent Dengue Vaccine
por: Braun, Ralph, et al.
Publicado: (2021)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)
por: White, Laura J., et al.
Publicado: (2021)

Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014)
por: L’Azou, Maïna, et al.
Publicado: (2018)

Induction of Neutralizing Antibody Response against Four Dengue Viruses in Mice by Intramuscular Electroporation of Tetravalent DNA Vaccines
por: Prompetchara, Eakachai, et al.
Publicado: (2014)

Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties
por: Liu, Yan, et al.
Publicado: (2014)

Plant‐expressed Fc‐fusion protein tetravalent dengue vaccine with inherent adjuvant properties
por: Kim, Mi Young, et al.
Publicado: (2018)

Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands
por: El Helou, Guy, et al.
Publicado: (2020)

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses
por: Nemirov, Kirill, et al.
Publicado: (2023)

Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine
por: El Fezzazi, Hanna, et al.
Publicado: (2017)

Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice
por: Kulkarni, Ajit, et al.
Publicado: (2017)

Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice
por: Fahimi, Hossein, et al.
Publicado: (2018)

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
por: Vigne, Claire, et al.
Publicado: (2017)

Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia
por: Reynales, Humberto, et al.
Publicado: (2020)

Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate
por: Imagawa, Toshifumi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r7iq923griv0r82k6c7l15vcdl